Nuformix PLC 29 November 2024 29 November 2024 Nuformix plc ("Nuformix" or the "Company") Total Voting Rights Following the issue of...
Nuformix PLC 05 November 2024 5 November 2024 Nuformix plc ("Nuformix" or the "Company" or the "Group") Director/PDMR Dealings ...
Nuformix PLC 04 November 2024 4 November 2024 Nuformix plc ("Nuformix" or the "Company") Result of General Meeting Nuformix plc...
Nuformix PLC 16 October 2024 THIS ANNOUNCEMENT AND THE INFORMATION IN IT, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION...
Nuformix PLC 20 September 2024 THIS ANNOUNCEMENT AND THE INFORMATION IN IT, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION...
ndon-based developer of treatments for fibrosis and oncology via drug repurposing - Posts no revenue in the six months ...
Nuformix PLC 18 June 2024 Nuformix plc ("Nuformix", the "Company" or the "Group") Half Year Report 18 June 2024: Nuformix plc (LSE:...
Nuformix PLC on Monday celebrated multiple patent wins, after grants in both Europe and the US signalled further prot ...
Nuformix PLC 17 June 2024 17 June 2024 Nuformix plc ("Nuformix" or the "Company") Patent Update Nuformix plc (LSE: NFX), a...
Nuformix PLC 19 March 2024 Nuformix plc ("Nuformix" or the "Company") Result of Annual General Meeting Nuformix plc (LSE: NFX), a...
ndon-based developer of treatments for fibrosis and oncology via drug repurposing - Announce intention to raise gross ...
Nuformix PLC 01 March 2024 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATIONS (EU...
Nuformix PLC 15 January 2024 15 January 2024 Nuformix plc ("Nuformix", the "Company" or the "Group") Posting of...
ndon-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 ...
Nuformix PLC 03 January 2024 3 January 2024 Nuformix plc ("Nuformix", the "Company" or the "Group") Annual Results...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads